Dr. Nasreen Najmunnisa, 2009 RC1 grantee at University of Florida, is developing novel methods for diagnosing and treating Non-Small Cell Lung Cancer (NSLC), which accounts for more deaths than prostate, breast, and colon cancer combined. “In NSLC, there is an excess of proteins, which are like the lock in a lock and key system. The key-like molecules can inhibit malignancy. We have identified the ‘lock’ molecule in NSCLC that promotes malignancy and are bioengineering nano-microspheres that function like a key. When a genetically engineered molecule (key) binds to the lock, malignancy can be suppressed.” Dr. Najmunnisa is pursuing a patent for this discovery.

The team is pursuing a new direction for NSCLC treatment by injecting microspheres directly into tumors. Unlike chemotherapy, there are no toxic side effects. The identified “lock” molecule may be useful as a diagnostic tool also. Dr. Najmunnisa is collaborating with physicians to move the research into clinical trials.

“Program funding has helped the university to retain and attract motivated scientists working on this project. Of the seven people on the project, two relocated to join this team because they are excited to work on the research.”

¹U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010.